This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Xin-Hua Xiao
the First Affiliated Hospital of University of South China
Corresponding Author
ORCiD: https://orcid.org/0000-0002-2706-4464
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objective: Asprosin, a new adipocytokine, has been reported to be related with glucose release, dyslipidemia and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aims to investigate serum asprosin levels in MetS as well as its association with various metabolic parameters in humans.
Methods: The consecutive 131 patients with MetS and age-matched 162 healthy subjects were recruited for this study. Serum asprosin concentrations were determined by ELISA. Lipid profile, glucose, insulin, and inflammatory markers were also measured.
Results: Serum asprosin levels were higher in subjects with MetS 23.52 (16.70, 32.05) ng/ml compared to 16.70 (12.87, 22.38) ng/ml in the controls (P < 0.01), and showed an increasing trend with the increased numbers of metabolic components (P for trend < 0.01). In all studied subjects, serum asprosin levels were positive correlated with body mass index, waist circumference, percentage of body fat (%), triglyceride, fasting plasma glucose, 2h plasma glucose, fasting insulin, HOMA-IR, interleukin (IL) -6 and monocyte chemoattractant protein (MCP)-1, and negative correlated with HDL cholesterol (P < 0.05). In a multiple linear regression, asprosin was independently and positively correlated with triglyceride and HOMA-IR (P < 0.05). Binary logistic regression revealed that asprosin was independently and positively correlated with the occurrence of MetS and IR even after controlling for anthropometric variables, lipid profiles and inflammatory markers.
Conclusion: Asprosin may be a metabolic - related adipokine and related to insulin resistance and MetS.
Trial Registration: ChiCTR, ChiCTR1800018347. Registered 12 September 2018, http://www.chictr.org.cn/showproj.aspx?proj=31050.
Keywords
Asprosin, metabolic syndrome, insulin resistance, adipocytokine
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 14 Aug, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Xin-Hua Xiao
the First Affiliated Hospital of University of South China
Corresponding Author
ORCiD: https://orcid.org/0000-0002-2706-4464
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 14 Aug, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objective: Asprosin, a new adipocytokine, has been reported to be related with glucose release, dyslipidemia and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aims to investigate serum asprosin levels in MetS as well as its association with various metabolic parameters in humans.
Methods: The consecutive 131 patients with MetS and age-matched 162 healthy subjects were recruited for this study. Serum asprosin concentrations were determined by ELISA. Lipid profile, glucose, insulin, and inflammatory markers were also measured.
Results: Serum asprosin levels were higher in subjects with MetS 23.52 (16.70, 32.05) ng/ml compared to 16.70 (12.87, 22.38) ng/ml in the controls (P < 0.01), and showed an increasing trend with the increased numbers of metabolic components (P for trend < 0.01). In all studied subjects, serum asprosin levels were positive correlated with body mass index, waist circumference, percentage of body fat (%), triglyceride, fasting plasma glucose, 2h plasma glucose, fasting insulin, HOMA-IR, interleukin (IL) -6 and monocyte chemoattractant protein (MCP)-1, and negative correlated with HDL cholesterol (P < 0.05). In a multiple linear regression, asprosin was independently and positively correlated with triglyceride and HOMA-IR (P < 0.05). Binary logistic regression revealed that asprosin was independently and positively correlated with the occurrence of MetS and IR even after controlling for anthropometric variables, lipid profiles and inflammatory markers.
Conclusion: Asprosin may be a metabolic - related adipokine and related to insulin resistance and MetS.
Trial Registration: ChiCTR, ChiCTR1800018347. Registered 12 September 2018, http://www.chictr.org.cn/showproj.aspx?proj=31050.
Figure 1
Figure 2
Loading...